The transcription factor nuclear factor B (NFB) is an essential antagonist of apoptosis during liver regeneration and embryonal development of hepatocytes. Several reports have indicated that NFB may also inhibit the programmed cell death induced by cytokines, ionizing radiation, or cytotoxic drugs in some cancer cell lines. Because hepatocellular carcinomas (HCCs) are one of the most resistant tumors to systemic chemotherapy, we investigated the activation of NFB and the consequence of its inhibition by an IB␣-super repressor during tumor necrosis factor ␣ (TNF␣)-and chemotherapy-induced apoptosis in HCC cell lines. We demonstrate that both TNF␣ and adriamycin activate NFB in hepatoma cells. Activation of NFB could be blocked through an adenoviral vector expressing the IB␣ super repressor, regardless of the activating agent. Inhibition of NFB enhanced the apoptosis induced by TNF␣, whereas IB␣ had an anti-apoptotic effect on chemotherapy-induced programmed cell death. A strong inhibition of chemotherapy-and TNF␣-induced apoptosis by dominant-negative Fas-associated death domain indicated an essential contribution of death receptor-mediated apoptosis. To elucidate the different role of NFB in chemotherapy-induced apoptosis, we investigated the expression of Fas (CD95) and Fas ligand (CD95 ligand), which have been described as important mediators of chemotherapy-induced cell death and as target genes of NFB. However, our investigations demonstrated that in hepatoma cells, the chemotherapy-induced up-regulation of Fas (CD95) and Fas ligand (CD95 ligand) is not transcriptionally mediated through NFB. Thus, other molecular mechanisms must account for the anti-apoptotic effect of IB␣ in adriamycin-induced death of hepatoma cells. In summary, our investigations indicate that the activation of NFB in response to cytotoxic drugs, in contrast to TNF␣, exerts a pro-apoptotic stimulus rather than an anti-apoptotic function, which has implications for therapy of HCCs. Cancer
C hemotherapeutic agents kill cancer cells mainly by programmed cell death. 1, 2 However, although some cancers are initially resistant to the apoptosis induced by chemotherapeutic agents, others become resistant to a broad spectrum of chemotherapeutic drugs during treatment. Hepatocellular carcinomas (HCCs) are some of the most resistant tumors to chemotherapy. The drug commonly used in the palliative systemic or regional treatment of HCC is the anthracycline adriamycin (ADM).
The cytotoxic effect of the antracyclines is thought to be the result of drug-induced DNA damage caused by different mechanisms. 3 The drug-induced cytotoxicity results in apoptosis, which is characterized by different morphological alterations such as cellular shrinkage, chromatin condensation, and internucleosomal DNA fragmentation. 1 The molecular events of drug-induced DNA damage and the induction of apoptosis have been the subject of many investigations during the last few years. Several apoptotic pathways have been discovered that execute chemotherapy-induced cell death. One of the most well-defined pathways is mediated by the surface receptors that belong to the tumor necrosis factor receptor (TNF-R) superfamily. 4 Members of this group (e.g., TNF-R, Fas (CD95), TNF-related apoptosis-inducing ligand-R1 (TRAIL-R1), and TRAIL-R2) contain cysteine-rich extracellular domains and homologous cytoplasmic sequences known as death domains. 5, 6 Triggering of the receptor by its ligand induces trimerization of the receptor, which allows the subsequent binding of an associated protein and in turn results in the activation of the caspase cascade, triggering apoptosis. Another important pathway involves the mitochondria, which upon activation release cytochrome c in the cytoplasm and also result in the activation of the caspase cascade and in the induction of apoptosis.
Nuclear factor B (NFB) is a transcription factor that has an important function in embryonal development and immune response. In particular in the liver, NFB has been described as an antagonist of apoptosis during tissue regeneration or embryonal development. [7] [8] [9] In quiescent cells, NFB is present in the cytoplasm as an inactive complex with an inhibitory IB subunit. Upon activation, IB becomes phosphorylated, ubiquinated, and then degraded, enabling the translocation of NFB into the nucleus, where it binds to the promoter regions of several genes and activates their transcription. 10 It is well established that under certain physiological conditions, the activation of NFB counteracts the apoptotic machinery. It has been demonstrated that NFB has a strong anti-apoptotic function in TNF␣-induced apoptosis 11, 12 However NFB also appears to be activated during chemotherapy, and it has been shown recently that it also mediates resistance to chemotherapy-induced cell death in some tumor cell lines. [13] [14] [15] To assess the role of NFB in the treatment of HCCs, we investigated the activation of NFB and its inhibition through adenoviral gene transfer of IB␣ during TNF␣-and chemotherapy-induced apoptosis in HCC cell lines.
MATERIALS AND METHODS

Cell lines
HepG2 cells derived from a human hepatoma and Huh7 cells derived from a human HCC were obtained from the American Type Culture Collection (Manassas, Va). A primary HCC cell line known as Tu5 was established from a resected, histologically confirmed HCC at the Medizinische Hochschule Hannover and was used as an early passage (Ͻ6) cell line for all experiments. All cells were maintained in growth medium (Dulbecco's modified Eagle's medium (DMEM)/Glutamax (Life Technologies, Gaithersburg, Md), supplemented with 10% heat-inactivated fetal bovine sera, 100 U/mL of penicillin, and 100 g of streptomycin) at 37°C in 5% CO 2 .
The adenoviral vectors Ad5-CMVLacZ (AdLacZ) and Ad5-CMVIB␣ (Ad-IB␣) were kindly provided by Dr. D. Brenner (University of North Carolina, Chapel Hill, NC).
8 Ad5-CMVdnFADD (Ad-dnFADD) was kindly provided by Dr. K. Streetz (Medizinische Hochschule Hannover).
Adenovirus preparation
To obtain high-titer viral stocks, 2 ϫ 10 8 293 adenoviral producer cells were infected at a multiplicity of infection (MOI) of 5-10 plaque-forming units per cell. The infected cells were grown for 3 days until a cytopathic effect could be seen and ϳ50% of the cells were detached. The cells were then collected and centrifuged. Viral particles were released by freezing the cells in liquid nitrogen and rapid thawing at 37°C four times. For further purification, the virus preparation was subjected to a 2-fold CsCl banding. CsCl banding and determination of infectivity by viral plaquing were performed according to standard protocols. Determination of infectivity and viral concentration was performed by standard plaque assay using 293 cells. Virus preparations were stored at Ϫ20°in 25% glycerol, 10 mM tris(hydroxymethyl)aminomethane/HCl (pH 7.4), and 1 mM MgCl 2 .
Infection
Before infection, cells were seeded at 1 ϫ 10 6 cells per 6-cm dish, and the medium was changed to DMEM supplemented with 2% fetal calf serum (FCS). Next, the adenoviral vectors were added and the cells were incubated for 24 hours at the indicated MOIs. Subsequently, the medium was changed to DMEM containing 10% FCS and cells were incubated for at least 5 hours before further treatment.
Treatment with anti-cancer agents and TNF␣
The different cell lines were treated with 2 g/mL ADM (Aventis, Strassbourg, France) or with 50 ng/mL human TNF␣ for the times indicated in the figures.
Whole-cell extracts and Western blot analysis
Whole cell extracts were obtained by sonification in 1% sodium dodecyl sulfate. A total of 10 g of protein was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel and blotted onto a Hybond N membrane (Millipore, Frankfurt, Germany). After blocking the membrane overnight with TBS-T buffer plus 5% dry milk, the preparation was incubated for 1 hour with the primary antibody (Ab) (anti-IB␣ (FLsc-847), Santa Cruz Biotechnology, Santa Cruz, Calif) or with anti-AU-1 for AU-1-tagged dominant-negative Fas-associated death domain (dnFADD) (AU-1 monoclonal Ab (mAb), Babco, Richmond, Calif). After washing, the secondary Ab (anti-rabbit Ab coupled to horseradish peroxidase; Santa Cruz Biotechnology) was added. The antigen-Ab complexes were visualized using the enhanced chemiluminescence detection system as recommended by the manufacturer (Amersham, Braunschweig, Germany).
Nuclear extracts and electrophoretic mobility shift assays (EMSAs)
Nuclear extracts were isolated from hepatoma cell lines (Huh7, HepG2, and Tu5) according to standard protocols using Dignam C. The protein concentration of nuclear extracts was measured by Bio-Rad microassay (Bio-Rad, München, Germany).
EMSA experiments were performed using nuclear extracts of hepatoma cells and 32 P-end-labeled, double-stranded oligonucleotides containing the NFB DNA binding site (5Ј-TAG-TTG-AGG-GGA-CTT-TCC-CAG-GCA-3Ј). For supershift experiments, an Ab against p65 was used (NFB p65 (A) sc-109 Santa Cruz Biotechnology).
Binding buffer consisted of 25 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.6), 5 mM MgCl 2 , 34 mM KCl, 2 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 1 g of poly(dI-dC)/L, and 2 g of bovine serum albumin/L. The binding reaction was incubated for 30 minutes on ice and subsequently separated in a 6% polyacrylamide gel. Electrophoresis was carried out for 4 hours at 300 V. After electrophoresis, the gel was dried and exposed for autoradiography.
Detection of apoptosis by fluorescence-activated cell sorter (FACS) analysis
Cells were trypsinized, washed several times with ice-cold phosphate-buffered saline (PBS), and stained as described previously. 16 Briefly, apoptotic nuclei were prepared by lysing cells in a hypotonic lysis buffer (1% sodium citrate, 0,1% Triton X-100, 50 g/mL propidium iodide), and apoptosis was analyzed subsequently by flow cytometry in a FACScan (FAC-Scalibur; Becton Dickinson, Heidelberg, Germany) with CellQuest analysis software using the FCS/FL2 profile.
Caspase 3 assay
The supernatant of cytosolic extracts was used for caspase 3 measurements with the CaspACE assay system (Promega, Madison, Wis). The assay was performed according to the instructions provided by the manufacturer.
Detection of Fas (CD95) and Fas ligand (FasL) (CD95 ligand (CD95L)) by FACS analysis
Cells were incubated with adenovirus and ADM as described previously. After a 6-hour incubation, plates were washed several times with ice-cold PBS containing 1% albumin (washing buffer). Cells were then incubated for 30 minutes at 4°C with the first Abs (anti-Fas (CD95) and Fas (Ab-2); Calbiochem-Novabiochem, Bad Soden, Germany) or anti-FasL (CD95L) (FasL (Ab-5); Calbiochem). After the incubation period, cells were washed again and incubated with the second fluorescein isothiocyanate-labeled Ab (fluorescein isothiocyanate anti-mouse immunoglobulin G 1 (A85-1); PharMingen, San Diego Calif). After 30 minutes, cells were washed and the pellet was resuspended in PBS plus 1% formaldehyde. Subsequently, a FACScan (FACScalibur, Becton Dickinson) was performed using the forward light scatter/FL1 protocol.
RESULTS
NFB nuclear translocation in hepatoma cells is induced by treatment with TNF␣ or chemotherapy and can be blocked by the IB␣ super repressor
To determine whether treatment with ADM or TNF␣ increases NFB activity in hepatoma cells, we examined NFB DNA binding activity in EMSAs using nuclear extracts from hepatoma cell lines treated with TNF␣ or ADM as indicated. We observed strong NFB activation through adenoviral infection and treatment with ADM or TNF␣ in Huh7 (Fig 1A) , HepG2, and Tu5 cells (data not shown).
To inhibit treatment-induced NFB activity, we used an adenoviral vector expressing the IB␣ super repressor. 8 The IB␣ super repressor is a nondegradable mutant of IB␣. The expression of the protein after adenoviral transduction of Huh7 (Fig 1B) , HepG2, and Tu5 cells (data not shown) was controlled by Western blot analysis. In cells infected with the IB␣-expressing adenovirus, NFB DNA binding activity was completely inhibited after TNF␣ and ADM treatment (Fig 1A) .
Contrary effects of IB␣ on ADM-and TNF␣-mediated apoptosis Earlier reports demonstrated that NFB plays an important role as an antagonist in TNF␣-induced apoptosis. In addition, there is evidence that NFB decreases the effect of chemotherapeutic drugs on programmed cell death in some cancer cell lines. [13] [14] [15] To evaluate this potential therapeutic option for the treatment of HCCs, we investigated the effect of gene therapy with IB␣ on ADM-and TNF␣-mediated apoptosis in a primary early passage HCC cell line (Tu5) and in the hepatoma cell lines HepG2 and Huh7 (Fig 2) . Cells expressing IB␣ and control cells infected with a lacZ-expressing adenovirus were treated with ADM or TNF␣. Cell death was assessed microscopically and by FACS analysis.
Our results confirmed that NFB generally exerts an anti-apoptotic function in the TNF␣ pathway (Fig  2) . In contrast, this effect was not observed in cells treated with chemotherapy. After infection with IB␣-expressing adenovirus, apoptosis was not enhanced in the primary HCC cell line Tu5 (Fig 2A) ; in HepG2 and Huh7 cells, a significantly higher percentage of apoptotic cells could be observed compared with control-treated cells (Fig 2, B and C) . Figure 2D shows the time course of ADM-induced apoptosis in Huh7 cells. Inhibition of NFB results in a delay in chemotherapy-induced cell death at 12 hours and in a reduced percentage of apoptosis at 24 hours and 36 hours (Fig 2D) . Therefore, our results demonstrated an anti-apoptotic effect rather than a proapoptotic function of IB␣ gene therapy on chemotherapyinduced apoptosis in hepatoma cells.
To confirm these results, we performed caspase 3 assays in Huh7 cells treated with ADM. Caspase 3 is involved as a key enzyme in the execution of apoptosis in response to different stimuli. ADM treatment results in the activation of caspase (Fig 3) . In accordance with the results of the FACS analysis, IB␣ gene therapy markedly inhibited the chemotherapy-induced increase in caspase 3 activity (Fig 3) .
Although NFB nuclear translocation in hepatoma cells is equally induced through the apoptotic stimuli TNF␣ and chemotherapy, we obtained different results regarding the role of NFB in apoptosis depending upon the apoptosis-inducing agent. In TNF␣-induced apoptosis, we could demonstrate the previously described antiapoptotic effect of NFB. However, in ADM-induced programmed cell death, the inhibition of NFB resulted in a decrease in apoptosis, suggesting that NFB has a proapoptotic function under these circumstances. 
ADM-and TNF␣-induced apoptosis of hepatoma cells is mediated through FADD
It is known that apoptosis can be mediated through different pathways. The most important apoptotic pathways involve the death receptors (TNF-R, TRAIL-R1, TRAIL-R2, Fas) and/or the mitochondria. Because NFB may have different functions in distinct apoptotic pathways, we investigated the contribution of the death receptor pathway on TNF␣-and ADM-induced apoptosis in hepatoma cells. FADD, the main protein connecting the death receptors with the caspase cascade, was inhibited by an adenoviral vector expressing dnFADD. Protein expression after adenovirus transduction was assessed by Western blot analysis (Fig 4A) .
By FACS analysis of hepatoma cells treated with TNF␣/cycloheximide or ADM, we could demonstrate that dnFADD resulted in a decrease of TNF␣/cycloheximide-and ADM-dependent apoptosis in hepatoma cells (Fig 4B) .
To confirm that the ADM-induced apoptosis of hepatoma cells is mainly mediated through FADD, we investigated the activation of caspase 3 in cells expressing dnFADD. In agreement with the data obtained by FACS analysis, a decrease of ADM-induced caspase 3 activity to the background level of the untreated control cells could be observed in cells expressing dnFADD. (Fig 4C) . These results indicated that the FADD pathway is essential in ADM-and TNF␣-induced apoptosis of hepatoma cells.
ADM-induced Fas (CD95) and FasL (CD95L) expression is independent of NFB in hepatoma cells
The important role of FADD indicates that a death receptor is involved in the ADM-induced programmed cell death of hepatoma cells. This observation is in agreement with previous investigations suggesting that Fas (CD95) and FasL (CD95L) mediate chemotherapyinduced apoptosis in hepatoma cells. 17 Recently NFB binding sites have been identified in the promoters of Fas (CD95) and FasL (CD95L). These binding sites seem to be of functional relevance during cytokine stimulation, oxidative stress, or chemotherapy-induced apoptosis. 18 -22 To assess whether NFB is also involved in the regulation of the Fas pathway in ADM-induced apoptosis in hepatoma cells and may therefore explain the contrary effect of the IB␣ gene therapy on TNF␣-and chemotherapy-induced apoptosis, we investigated the influence of NFB on Fas (CD95) and FasL (CD95L) protein expression by FACS analysis.
A significant increase of Fas (CD95) and FasL (CD95L) due to ADM treatment could be demonstrated in all cells investigated (Fig 5) . Next, we determined whether inhibition of NFB activation resulted in an inhibition of Fas (CD95) or FasL (CD95L) expression. Cells expressing IB␣ were treated with ADM, and the status of the Fas (CD95) receptor and ligand was compared with control-treated cells. No difference in the expression of both proteins could be observed when NFB activity was inhibited (Fig 5) .
These results demonstrate that ADM leads to an up-regulation of Fas (CD95) as well as FasL (CD95L) in hepatoma cells. Because this up-regulation is not inhibited by IB␣ gene therapy, other molecular mechanisms must account for the anti-apoptotic effect of IB␣ in ADM-mediated apoptosis of hepatoma cells.
DISCUSSION
Resistance to chemotherapy is a general problem of cancer therapy. Particularly in HCCs, the efficacy of systemic chemotherapy is often neglectable and toxicity outweighs the potential palliative effect of antineoplastic agents. Several investigations over the last few years indicate that the regulation of apoptotic cell death has an important function in determining the sensitivity of tumor cells to chemotherapy. 23 A relevant molecule in this scenario appears to be the transcription factor NFB. NFB is ubiquitously expressed and regulates many important genes that are involved in embryonal development, the immune response, and apoptosis. 24 It has been demonstrated that NFB exhibits a strong anti-apoptotic signal in TNF␣-induced apoptosis. There is also evidence that NFB decreases the apoptotic effect in chemotherapy-or radiation-induced programmed cell death in some cell types. [13] [14] [15] Because NFB plays a major role as an essential survival factor in the embryonal development of the liver and during liver regeneration, [7] [8] [9] we hypothesized that inhibiting NFB activation through the IB␣ super repressor might improve chemotherapy-and TNF␣-induced apoptosis in HCCs. To exclude cell line-specific effects, two established hepatoma cell lines as well as a primary early passage cell line that had been isolated from a human HCC were included. TNF␣ treatment resulted in a strong NFB activation. However, the same effect was evident when the cells were treated with ADM. This led to the suggestion that NFB plays an important anti-apoptotic role in the cell death induced by both agents. To investigate the role of NFB in chemotherapy-and TNF␣-induced apoptosis of hepatoma cells, the translocation of NFB to the nucleus was inhibited by infecting the cells with an adenoviral vector expressing the IB␣ super repressor.
In agreement with other investigators, [11] [12] [13] 15 we were able to observe enhanced apoptosis after IB␣ gene therapy in hepatoma cells treated with TNF␣. In contrast to TNF␣, chemotherapy-induced apoptosis was not enhanced by blocking NFB. After chemotherapy, there was decrease in apoptosis in hepatoma cell lines infected with the IB␣ adenoviral vector compared with normal control cells in which NFB activation remained intact. This observation is in conflict with a previous published study that demonstrated a strong synergistic proapoptotic effect of an adenoviral vector expressing IB␣ super repressor and chemotherapy with Irinotecan (CPT-11) in fibrosarcoma cells. 15 Currently, we are unable to explain the discrepancies in our results. Because other studies demonstrated that stable IB␣ expression enhances the chemosensitivity of fibrosarcoma cells to anthracylins, 13 cytostatic agent-specific effects do not seem to account for the different observations. However, cell type-specific differences in the apoptotic machinery have to be considered as a possible explanation for these conflicting results.
It has been demonstrated that the activation of TNF-R-associated factor, inhibitor of apoptosis protein, IEX-1, X-linked inhibitor of apoptosis protein, and A1/Bfl-1 by NFB mediates resistance to several apoptotic stimuli in some cell types. [25] [26] [27] [28] [29] In chemotherapyinduced apoptosis, NFB appears to mediate cell survival through the induction of Bcl2, which in turn blocks the release of cytochrome c from the mitochondria, resulting in an inhibition of caspase 3, one of the main effector caspases during apoptosis. 29 To confirm our results, we investigated the effect of NFB on caspase 3 in chemotherapy-induced apoptosis in hepatoma cells. We were able to observe a down-regulation of caspase 3 in cells pretreated with the IB␣-expressing adenovirus, which supports our finding that NFB exerts a proapoptotic rather than an anti-apoptotic function during chemotherapy of hepatoma cells. Our results suggest that the role of NFB in programmed cell death depends upon the apoptosis-inducing agent. We and other investigators demonstrated a strong anti-apoptotic function of NFB in TNF␣-induced apoptosis. However in chemotherapy-induced apoptosis, NFB seems to play a different role, which appears to be more cell typedependent.
Apoptosis is triggered through death receptors of the cell membrane and/or cytochrome c release from the mitochondria. To investigate whether the different role of NFB can be explained by the induction of different apoptotic pathways, we investigated the contribution of FADD in TNF␣-and ADM-mediated apoptosis of hepatoma cells. The death receptors (Fas (CD95), TNF-R, TRAIL-R1, and TRAIL-R2) are known to be connected to the caspase cascade by FADD. 30 The strong inhibition of apoptosis by dnFADD in our experiments indicated that the FADD pathway is essential not only in TNF␣-but also in ADM-mediated apoptosis of hepatoma cells.
It has been shown recently that ADM-induced programmed cell death of hepatoma cells is mainly mediated by the Fas (CD95) pathway. 17 However, Fas (CD95)-independent mechanisms may also account for chemotherapy-induced apoptosis of hepatoma cells. 31 Because functionally relevant NFB binding sites have been identified in the Fas (CD95) and FasL (CD95L) promotors, 18 -22 we investigated the hypothesis that IB␣ gene therapy may inhibit the chemotherapy-induced expression of Fas (CD95) or FasL (CD95L) in hepatoma cells. The increase in Fas (CD95) and FasL (CD95L) expression, induced by ADM treatment, could not be inhibited by IB␣, which indicates that in contrast to lymphocytes, 19, 22 NFB activation does not account for the up-regulation of Fas (CD95) expression in hepatoma cell lines.
The function of NFB in the treatment of hepatoma cells with ADM remains unclear. The NFB pathway is a key mechanism of the cellular response to a variety of extracellular stimuli, which all have in common that they signal situations of stress, infection, or injury of the organism. There is also evidence that NFB activation, alone or in combination with other events, is necessary to induce apoptosis in response to certain stimuli. For example, target gene activation of interferon regulatory factor-1 32, 33 and of caspases such as caspase 1 34 by NFB have been described previously and may explain, at least in part, the proapoptotic role of NFB in the chemotherapy of hepatoma cells.
In summary, our results demonstrate that TNF␣ as well as ADM activates the nuclear translocation of NFB in hepatoma cell lines. However, ADM-induced apoptosis, in contrast to TNF␣-mediated apoptosis, was not enhanced after the administration of an IB␣-expressing adenovirus. Inhibition of NFB activation during chemotherapy leads to a decrease of apoptosis and to a reduction in caspase 3 activity, suggesting that NFB exerts a proapoptotic function in the chemotherapy of hepatoma cells.
